替吉奥胶囊单药三线治疗老年晚期结直肠癌的疗效分析

Analysis of Efficacy of S-1 Capsale Monotherapy Third-line Treatment in Elderly Patients with Advanced Colorectal Cancer

目的探讨替吉奥胶囊单药三线治疗老年晚期结直肠癌的临床疗效。方法选取我院2013年8月至2014年8月收治的老年晚期结直肠癌患者66例,采用随机数字法将其分为观察组与对照组,每组33例,观察组患者应用三线替吉奥胶囊单药治疗,对照组患者应用卡培他滨片治疗,观察对比两组患者使用药物疗效及不良反应。结果观察组患者的临床有效率为45.45%,对照组为42.42%,两组患者对比无显著差异(P>0.05);观察组患者KPS评分改善明显高于对照组,两组对比差异显著(P<0.05);观察组患者腹泻及手足综合证的发生率明显低于对照组,两组患者对比差异显著(P<0.05)。结论老年晚期结直肠癌患者应用替吉奥胶囊单药三线治疗临床疗效确切,不良反应较小,给药方便,可提高患者生活质量,同时患者耐受能力较高,值得临床治疗进一步应用及推广。

Objective To investigate the clinical efficacy of S-1 monotherapy third-line treatment in elderly patients with advanced colorectal cancer. Methods 66 cases of senile advanced colorectal cancer patients were selected in our hospital from August 2013 to August 2014, who were randomly divided into the observation group and the control group with 33 cases in each group. In observation group, third-line S-1 monotherapy was applicated, while the patients in control group were treated with capecitabine tablets. The efficacy and side effects of the drugs were observed and compared between the two groups of patients. Results In the observation group patients, the clinical effective rate was 45.45%, while it was 42.42% in the control group. There was no significant difference （P 〉 0.05） between the two groups of patients. Improvement of KPS score in the observation group was significantly higher than that of the control group with significant difference between the two groups （P 〈 0.05）.Diarrhea and hand foot syndrom incidence in observation group was significantly lower than that of the control group, which was significantly different （P 〈 0.05）. Conclusion In elderly patients with advanced colorectal cancer, S-1 capsule monotherapy third-line treatment is effective with less adverse reactions and dosing convenience. It can improve the life quality of patients, also with a higher tolerance. It is worthy to be further applicated and promoted in clinic.